These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1041 related articles for article (PubMed ID: 31388723)

  • 1. IDH-wildtype glioblastomas and grade III/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein-specific PET/CT.
    Röhrich M; Loktev A; Wefers AK; Altmann A; Paech D; Adeberg S; Windisch P; Hielscher T; Flechsig P; Floca R; Leitz D; Schuster JP; Huber PE; Debus J; von Deimling A; Lindner T; Haberkorn U
    Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2569-2580. PubMed ID: 31388723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FAP-specific PET signaling shows a moderately positive correlation with relative CBV and no correlation with ADC in 13 IDH wildtype glioblastomas.
    Röhrich M; Floca R; Loi L; Adeberg S; Windisch P; Giesel FL; Kratochwil C; Flechsig P; Rathke H; Lindner T; Loktev A; Schlemmer HP; Haberkorn U; Paech D
    Eur J Radiol; 2020 Jun; 127():109021. PubMed ID: 32344293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of Fibroblast Activation Protein in Glioblastoma and Gliosarcoma: A Comparison of Tissue,
    Oster C; Kessler L; Blau T; Keyvani K; Pabst KM; Fendler WP; Fragoso Costa P; Lazaridis L; Schmidt T; Feldheim J; Pierscianek D; Schildhaus HU; Sure U; Ahmadipour Y; Kleinschnitz C; Guberina N; Stuschke M; Deuschl C; Scheffler B; Herrmann K; Kebir S; Glas M
    J Nucl Med; 2024 Aug; 65(8):1217-1223. PubMed ID: 38960714
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Giesel FL; Kratochwil C; Lindner T; Marschalek MM; Loktev A; Lehnert W; Debus J; Jäger D; Flechsig P; Altmann A; Mier W; Haberkorn U
    J Nucl Med; 2019 Mar; 60(3):386-392. PubMed ID: 30072500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein.
    Lindner T; Loktev A; Altmann A; Giesel F; Kratochwil C; Debus J; Jäger D; Mier W; Haberkorn U
    J Nucl Med; 2018 Sep; 59(9):1415-1422. PubMed ID: 29626119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Fibroblast Activation Protein: Radiosynthesis and Preclinical Evaluation of an
    Toms J; Kogler J; Maschauer S; Daniel C; Schmidkonz C; Kuwert T; Prante O
    J Nucl Med; 2020 Dec; 61(12):1806-1813. PubMed ID: 32332144
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Lanzafame H; Mavroeidi IA; Pabst KM; Desaulniers M; Ingenwerth M; Hirmas N; Kessler L; Nader M; Bartel T; Leyser S; Barbato F; Schuler M; Bauer S; Siveke JT; Herrmann K; Hamacher R; Fendler WP
    J Nucl Med; 2024 Jun; 65(6):880-887. PubMed ID: 38724279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and Development of
    Lindner T; Altmann A; Krämer S; Kleist C; Loktev A; Kratochwil C; Giesel F; Mier W; Marme F; Debus J; Haberkorn U
    J Nucl Med; 2020 Oct; 61(10):1507-1513. PubMed ID: 32169911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status.
    Roodakker KR; Elsir T; Edqvist PD; Hägerstrand D; Carlson J; Lysiak M; Henriksson R; Pontén F; Rosell J; Söderkvist P; Stupp R; Tchougounova E; Nistér M; Malmström A; Smits A
    Oncotarget; 2016 Nov; 7(45):72431-72442. PubMed ID: 27626492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-invasive prediction of IDH-wildtype genotype in gliomas using dynamic
    Vettermann F; Suchorska B; Unterrainer M; Nelwan D; Forbrig R; Ruf V; Wenter V; Kreth FW; Herms J; Bartenstein P; Tonn JC; Albert NL
    Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2581-2589. PubMed ID: 31410540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Theranostics Targeting Fibroblast Activation Protein in the Tumor Stroma:
    Watabe T; Liu Y; Kaneda-Nakashima K; Shirakami Y; Lindner T; Ooe K; Toyoshima A; Nagata K; Shimosegawa E; Haberkorn U; Kratochwil C; Shinohara A; Giesel F; Hatazawa J
    J Nucl Med; 2020 Apr; 61(4):563-569. PubMed ID: 31586001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of Fibroblast Activation Protein-Targeted Radiotracers with Improved Tumor Retention.
    Loktev A; Lindner T; Burger EM; Altmann A; Giesel F; Kratochwil C; Debus J; Marmé F; Jäger D; Mier W; Haberkorn U
    J Nucl Med; 2019 Oct; 60(10):1421-1429. PubMed ID: 30850501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibroblast Activation Protein-Specific PET/CT Imaging in Fibrotic Interstitial Lung Diseases and Lung Cancer: A Translational Exploratory Study.
    Röhrich M; Leitz D; Glatting FM; Wefers AK; Weinheimer O; Flechsig P; Kahn N; Mall MA; Giesel FL; Kratochwil C; Huber PE; Deimling AV; Heußel CP; Kauczor HU; Kreuter M; Haberkorn U
    J Nucl Med; 2022 Jan; 63(1):127-133. PubMed ID: 34272325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Static
    Song S; Wang L; Yang H; Shan Y; Cheng Y; Xu L; Dong C; Zhao G; Lu J
    Eur Radiol; 2021 Jun; 31(6):4087-4096. PubMed ID: 33211141
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Kratochwil C; Flechsig P; Lindner T; Abderrahim L; Altmann A; Mier W; Adeberg S; Rathke H; Röhrich M; Winter H; Plinkert PK; Marme F; Lang M; Kauczor HU; Jäger D; Debus J; Haberkorn U; Giesel FL
    J Nucl Med; 2019 Jun; 60(6):801-805. PubMed ID: 30954939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of FAPI Tetramers to Improve Tumor Uptake and Efficacy of FAPI Radioligand Therapy.
    Pang Y; Zhao L; Fang J; Chen J; Meng L; Sun L; Wu H; Guo Z; Lin Q; Chen H
    J Nucl Med; 2023 Sep; 64(9):1449-1455. PubMed ID: 37321827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Hedgehog pathway responsive glioblastomas by isocitrate dehydrogenase mutation.
    Gerardo Valadez J; Grover VK; Carter MD; Calcutt MW; Abiria SA; Lundberg CJ; Williams TV; Cooper MK
    Cancer Lett; 2013 Jan; 328(2):297-306. PubMed ID: 23063752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TSPO PET, tumour grading and molecular genetics in histologically verified glioma: a correlative
    Unterrainer M; Fleischmann DF; Vettermann F; Ruf V; Kaiser L; Nelwan D; Lindner S; Brendel M; Wenter V; Stöcklein S; Herms J; Milenkovic VM; Rupprecht R; Tonn JC; Belka C; Bartenstein P; Niyazi M; Albert NL
    Eur J Nucl Med Mol Imaging; 2020 Jun; 47(6):1368-1380. PubMed ID: 31486876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of [
    Liu N; Wan Q; Wu X; Zhao T; Jakobsson V; Yuan H; Chen X; Zhang J; Zhang W
    Eur J Nucl Med Mol Imaging; 2024 May; 51(6):1685-1697. PubMed ID: 38246909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibroblast Activation Protein Targeting Probe with Gly-Pro Sequence for PET of Glioblastoma.
    Lai C; Cao R; Li R; He C; Wang X; Shi H; Qu C; Qian K; Song S; Chen WH; Cheng Z
    Mol Pharm; 2023 Aug; 20(8):4120-4128. PubMed ID: 37487027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.